Pharma BD Deal Intelligence
Eli Lilly agreed to acquire Calytrix Bio, a preclinical-stage biotech in Wellesley Hills, Massachusetts developing precision, disease-modifying therapies for myeloproliferative neoplasms. Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment plus subsequent payments contingent on achievement of certain clinical and regulatory milestones. Calytrix's lead program is a biparatopic antibody designed to target both Type 1 and Type 2 mutant calreticulin (mCALR), the driver mutation in a subset of patients with essential thrombocythemia and myelofibrosis. The company was founded by J.P. Morgan Life Sciences Private Capital, with Westlake BioPartners co-leading its Series A and Avoro Ventures leading its Series B. Lilly's stated aim is to alter disease course in mCALR-driven ET and MF rather than manage symptoms.